{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T06:33:49Z","timestamp":1763706829760,"version":"3.40.5"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:00:00Z","timestamp":1720137600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemistry and Biophysics Reports"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.bbrep.2024.101781","type":"journal-article","created":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T14:48:06Z","timestamp":1720363686000},"page":"101781","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Proteasome and PARP1 dual-target inhibitor for multiple myeloma: Fluzoparib"],"prefix":"10.1016","volume":"39","author":[{"given":"Kai","family":"Deng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiongqiong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7216-3114","authenticated-orcid":false,"given":"Suyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrep.2024.101781_bib1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s11899-018-0456-8","article-title":"Updates in the pathology of precursor lymphoid neoplasms in the revised fourth edition of the WHO classification of tumors of hematopoietic and lymphoid tissues","volume":"13","author":"Wenzinger","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.bbrep.2024.101781_bib2","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-term follow-up of monoclonal gammopathy of undetermined significance","volume":"378","author":"Kyle","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrep.2024.101781_bib3","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10555-017-9707-8","article-title":"The proteasome and proteasome inhibitors in multiple myeloma","volume":"36","author":"Gandolfi","year":"2017","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.bbrep.2024.101781_bib4","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1200\/JCO.2005.11.030","article-title":"Proteasome inhibition as a novel therapeutic target in human cancer","volume":"23","author":"Rajkumar","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbrep.2024.101781_bib5","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","article-title":"Proteasome inhibitors in cancer therapy","volume":"14","author":"Manasanch","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbrep.2024.101781_bib6","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1038\/leu.2016.102","article-title":"Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism","volume":"30","author":"Soriano","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrep.2024.101781_bib7","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1124\/pr.117.015370","article-title":"A practical review of proteasome pharmacology","volume":"71","author":"Thibaudeau","year":"2019","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bbrep.2024.101781_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trsl.2018.03.002","article-title":"Next-generation proteasome inhibitors for cancer therapy","volume":"198","author":"Park","year":"2018","journal-title":"Transl. Res."},{"key":"10.1016\/j.bbrep.2024.101781_bib9","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2308417120","article-title":"Rational design of proteasome inhibitors based on the structure of the endogenous inhibitor PI31\/Fub1","volume":"120","author":"Velez","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bbrep.2024.101781_bib10","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrm.2017.53","article-title":"The multifaceted roles of PARP1 in DNA repair and chromatin remodelling","volume":"18","author":"Ray Chaudhuri","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bbrep.2024.101781_bib11","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nrc2812","article-title":"PARP inhibition: PARP1 and beyond","volume":"10","author":"Rouleau","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrep.2024.101781_bib12","doi-asserted-by":"crossref","first-page":"6368","DOI":"10.1182\/blood-2011-06-363911","article-title":"Bortezomib-induced \"BRCAness\" sensitizes multiple myeloma cells to PARP inhibitors","volume":"118","author":"Neri","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbrep.2024.101781_bib13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41408-022-00643-3","article-title":"Extramedullary disease in multiple myeloma: a systematic literature review","volume":"12","author":"Blade","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.bbrep.2024.101781_bib14","doi-asserted-by":"crossref","first-page":"408","DOI":"10.5271\/sjweh.3960","article-title":"Return-to-work, disabilities and occupational health in the age of COVID-19","volume":"47","author":"Godeau","year":"2021","journal-title":"Scand. J. Work. Environ. Health"},{"key":"10.1016\/j.bbrep.2024.101781_bib15","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/dom.12015","article-title":"Combine and conquer: advantages and disadvantages of fixed-dose combination therapy","volume":"15","author":"Bell","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.bbrep.2024.101781_bib16","doi-asserted-by":"crossref","first-page":"59","DOI":"10.12793\/tcp.2019.27.2.59","article-title":"A review of computational drug repurposing","volume":"27","author":"Park","year":"2019","journal-title":"Transl Clin Pharmacol"},{"key":"10.1016\/j.bbrep.2024.101781_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2020.100713","article-title":"Repurposing old drugs to fight multidrug resistant cancers","volume":"52","author":"Dinic","year":"2020","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.bbrep.2024.101781_bib18","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1186\/s12859-019-3238-y","article-title":"Old drug repositioning and new drug discovery through similarity learning from drug-target joint feature spaces","volume":"20","author":"Zheng","year":"2019","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.bbrep.2024.101781_bib19","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/nrd1900","article-title":"Finding new tricks for old drugs: an efficient route for public-sector drug discovery","volume":"4","author":"O'Connor","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbrep.2024.101781_bib20","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1007\/s12272-015-0640-5","article-title":"Role of computer-aided drug design in modern drug discovery","volume":"38","author":"Macalino","year":"2015","journal-title":"Arch Pharm. Res. (Seoul)"},{"key":"10.1016\/j.bbrep.2024.101781_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101729","article-title":"Targeting transcriptional kinase of CDK7 halts proliferation of multiple myeloma cells by modulating the function of canonical NF-kB pathway and cell cycle regulatory proteins","volume":"35","author":"Dutta","year":"2023","journal-title":"Transl Oncol"},{"key":"10.1016\/j.bbrep.2024.101781_bib22","article-title":"Transcriptomic characterization revealed that METTL7A inhibits melanoma progression via the p53 signaling pathway and immunomodulatory pathway","volume":"11","author":"Zhang","year":"2023","journal-title":"PeerJ"},{"key":"10.1016\/j.bbrep.2024.101781_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120402","article-title":"Telomerase inhibition on acute myeloid leukemia stem cell induced apoptosis with both intrinsic and extrinsic pathways","volume":"295","author":"Rafat","year":"2022","journal-title":"Life Sci."},{"key":"10.1016\/j.bbrep.2024.101781_bib24","doi-asserted-by":"crossref","first-page":"e426","DOI":"10.1002\/ctm2.426","article-title":"m(6) A modification of lncRNA PCAT6 promotes bone metastasis in prostate cancer through IGF2BP2-mediated IGF1R mRNA stabilization","volume":"11","author":"Lang","year":"2021","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.bbrep.2024.101781_bib25","first-page":"175","article-title":"Comparative study of gavage and intraperitoneal administration of gamma-oryzanol in alleviation\/attenuation in a rat animal model of renal ischemia\/reperfusion-induced injury","volume":"24","author":"Bagheri","year":"2021","journal-title":"Iran J Basic Med Sci"},{"key":"10.1016\/j.bbrep.2024.101781_bib26","first-page":"1222","article-title":"Mesenchymal stem cells cause induction of granulocyte differentiation of rat bone marrow C-kit(+) hematopoietic stem cells through JAK3\/STAT3, ERK, and PI3K signaling pathways","volume":"25","author":"Fathi","year":"2022","journal-title":"Iran J Basic Med Sci"},{"key":"10.1016\/j.bbrep.2024.101781_bib27","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1007\/s11655-020-3421-y","article-title":"Morinda citrifolia (noni) juice suppresses A549 human lung cancer cells via inhibiting AKT\/nuclear factor-kappa B signaling pathway","volume":"27","author":"Ma","year":"2021","journal-title":"Chin. J. Integr. Med."},{"key":"10.1016\/j.bbrep.2024.101781_bib28","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12987-023-00470-z","article-title":"Proteasome inhibition protects blood-brain barrier P-glycoprotein and lowers Abeta brain levels in an Alzheimer's disease model","volume":"20","author":"Vulin","year":"2023","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.bbrep.2024.101781_bib29","doi-asserted-by":"crossref","DOI":"10.3892\/ijmm.2021.4863","article-title":"Paris saponin H inhibits the proliferation of glioma cells through the A1 and A3 adenosine receptor-mediated pathway","volume":"47","author":"Bi","year":"2021","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.bbrep.2024.101781_bib30","first-page":"G1061","article-title":"Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice","volume":"274","author":"Sawaoka","year":"1998","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.bbrep.2024.101781_bib31","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1093\/bioinformatics\/btz976","article-title":"ChemBioServer 2.0: an advanced web server for filtering, clustering and networking of chemical compounds facilitating both drug discovery and repurposing","volume":"36","author":"Karatzas","year":"2020","journal-title":"Bioinformatics"},{"key":"10.1016\/j.bbrep.2024.101781_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14225621","article-title":"Guggulsterone induces apoptosis in multiple myeloma cells by targeting high mobility group box 1 via janus activated kinase\/signal transducer and activator of transcription pathway","volume":"14","author":"Akhtar","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.bbrep.2024.101781_bib33","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12943-020-01227-0","article-title":"PARP inhibitor resistance: the underlying mechanisms and clinical implications","volume":"19","author":"Li","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbrep.2024.101781_bib34","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-pharmtox-010919-023603","article-title":"Proteasome inhibitor drugs","volume":"60","author":"Fricker","year":"2020","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.bbrep.2024.101781_bib35","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrep.2024.101781_bib36","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1161\/ATVBAHA.108.167197","article-title":"Mertk receptor mutation reduces efferocytosis efficiency and promotes apoptotic cell accumulation and plaque necrosis in atherosclerotic lesions of apoe-\/- mice","volume":"28","author":"Thorp","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.bbrep.2024.101781_bib37","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.cbpa.2008.06.033","article-title":"Advances in and applications of proteasome inhibitors","volume":"12","author":"Moore","year":"2008","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.bbrep.2024.101781_bib38","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1002\/cncr.32659","article-title":"Hematopoietic stem cell transplantation for blood cancers in the era of precision medicine and immunotherapy","volume":"126","author":"Bair","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.bbrep.2024.101781_bib39","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1172\/JCI129205","article-title":"Immunotherapy of multiple myeloma","volume":"130","author":"Minnie","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbrep.2024.101781_bib40","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.bbrep.2024.101781_bib41","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1146\/annurev-med-050522-033815","article-title":"New biological therapies for multiple myeloma","volume":"75","author":"Garfall","year":"2024","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.bbrep.2024.101781_bib42","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1038\/sj.leu.2403905","article-title":"Novel targeted drugs for the treatment of multiple myeloma: from bench to bedside","volume":"19","author":"Bruno","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrep.2024.101781_bib43","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.3324\/haematol.2011.051169","article-title":"Can multiple myeloma become a curable disease?","volume":"96","author":"San-Miguel","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.bbrep.2024.101781_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020407","article-title":"Multiple myeloma: available therapies and causes of drug resistance","volume":"12","author":"Pinto","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.bbrep.2024.101781_bib45","doi-asserted-by":"crossref","first-page":"370","DOI":"10.21147\/j.issn.1000-9604.2020.03.08","article-title":"Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors","volume":"32","author":"Li","year":"2020","journal-title":"Chin. J. Cancer Res."},{"key":"10.1016\/j.bbrep.2024.101781_bib46","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00432-019-03097-6","article-title":"Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1\/2 mutation, a novel PARP1 inhibitor undergoing clinical trials","volume":"146","author":"Luo","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.bbrep.2024.101781_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9081024","article-title":"Therapeutic potential of PARP inhibitors in the treatment of gastrointestinal cancers","volume":"9","author":"Alhusaini","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.bbrep.2024.101781_bib48","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40265-021-01541-x","article-title":"Fuzuloparib: first approval","volume":"81","author":"Lee","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.bbrep.2024.101781_bib49","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1111\/cas.13947","article-title":"Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials","volume":"110","author":"Wang","year":"2019","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bbrep.2024.101781_bib50","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0962-8924(98)01346-4","article-title":"Proteasome inhibitors: valuable new tools for cell biologists","volume":"8","author":"Lee","year":"1998","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.bbrep.2024.101781_bib51","first-page":"471","article-title":"The 19 S multicatalytic \"prosome\" proteinase is a constitutive enzyme in HeLa cells","volume":"17","author":"Hendil","year":"1988","journal-title":"Biochem. Int."},{"key":"10.1016\/j.bbrep.2024.101781_bib52","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.drup.2006.11.001","article-title":"The proteasome as a potential target for novel anticancer drugs and chemosensitizers","volume":"9","author":"Landis-Piwowar","year":"2006","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.bbrep.2024.101781_bib53","first-page":"2638","article-title":"The proteasome inhibitor PS-341 in cancer therapy","volume":"5","author":"Teicher","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrep.2024.101781_bib54","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nrclinonc.2014.200","article-title":"Current treatment landscape for relapsed and\/or refractory multiple myeloma","volume":"12","author":"Dimopoulos","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbrep.2024.101781_bib55","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1182\/bloodadvances.2022007875","article-title":"SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma","volume":"7","author":"Heynen","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.bbrep.2024.101781_bib56","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1101\/gad.183509.111","article-title":"On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1","volume":"26","author":"Luo","year":"2012","journal-title":"Genes Dev."},{"key":"10.1016\/j.bbrep.2024.101781_bib57","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.1093\/nar\/gkz120","article-title":"Poly(ADP-ribosyl)ation by PARP1: reaction mechanism and regulatory proteins","volume":"47","author":"Alemasova","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbrep.2024.101781_bib58","doi-asserted-by":"crossref","DOI":"10.3390\/cells8121625","article-title":"The enigmatic function of PARP1: from PARylation activity to PAR readers","volume":"8","author":"Kamaletdinova","year":"2019","journal-title":"Cells"}],"container-title":["Biochemistry and Biophysics Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405580824001456?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405580824001456?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T15:27:45Z","timestamp":1725204465000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405580824001456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":58,"alternative-id":["S2405580824001456"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrep.2024.101781","relation":{},"ISSN":["2405-5808"],"issn-type":[{"type":"print","value":"2405-5808"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proteasome and PARP1 dual-target inhibitor for multiple myeloma: Fluzoparib","name":"articletitle","label":"Article Title"},{"value":"Biochemistry and Biophysics Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrep.2024.101781","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101781"}}